MONARCH 3: Abemaciclib as initial therapy for patients with HR+, HER2-advanced breast cancer - Results from the preplanned final PFS analysis

被引：1
|
作者：
Goetz, Matthew P. [1 ]
Martin, Miguel [2 ,3 ]
Di Leo, Angelo [4 ]
Im, Seock-Ah [5 ]
Awada, Ahmad [6 ]
Forrester, Tammy [7 ]
Frenzel, Martin [7 ]
Cox, Joanne [8 ]
Barriga, Susana [9 ]
Toi, Masakazu [10 ]
Iwata, Hiroji [11 ]
Johnston, Stephen [12 ]
机构：
[1] Mayo Clin, Rochester, MN USA
[2] Geicam, Inst Invest Sanitaria Gregorio Maranon, Ciberonc, Madrid, Spain
[3] Univ Complutense, Madrid, Spain
[4] Hosp Prato, Prato, Italy
[5] Seoul Natl Univ, Seoul Natl Univ Hosp, Coll Med, Seoul, South Korea
[6] Jules Bordet Inst, Brussels, Belgium
[7] Eli Lilly & Co, Indianapolis, IN 46285 USA
[8] Eli Lilly & Co, Windlesham, Surrey, England
[9] Eli Lilly & Co, Madrid, Spain
[10] Kyoto Univ, Kyoto, Japan
[11] Aichi Canc Ctr Hosp, Nagoya, Aichi, Japan
[12] Royal Marsden NHS Fdn Trust, London, England
来源：
CANCER RESEARCH | 2018年 / 78卷 / 13期
关键词：
D O I：
10.1158/1538-7445.AM2018-CT040
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
CT040
引用
收藏
页数：2
相关论文
共 50 条
  • [1] MONARCH 3: Abemaciclib as initial therapy for patients with HR+/HER2-advanced breast cancer
    Di Leo, A.
    Toi, M.
    Campone, M.
    Sohn, J.
    Paluch-Shimon, S.
    Huober, J.
    Park, I. H.
    Tredan, O.
    Chen, S-C.
    Manso, L.
    Freedman, O.
    Jaliffe, G. G.
    Forrester, T.
    Frenzel, M.
    Barriga, S.
    Smith, I. C.
    Bourayou, N.
    Goetz, M. P.
    ANNALS OF ONCOLOGY, 2017, 28
  • [2] MONARCH 3: Abemaciclib as Initial Therapy for Patients with HR+/HER2-Advanced Breast Cancer
    Leo, A. D.
    Toi, M.
    Campone, M.
    Sohn, J. H.
    Shimon, S. P.
    Huober, J.
    Park, I. H.
    Tredan, O.
    Chen, S. -C.
    Manso, L.
    Freedman, O.
    Jaliffe, G. G.
    Forrester, T. D.
    Frenzel, M.
    Barriga, S.
    Smith, I. C.
    Bourayou, N.
    Goetz, M. P.
    ONCOLOGY RESEARCH AND TREATMENT, 2018, 41 : 5 - 5
  • [3] Abemaciclib in combination with endocrine therapy for East Asian patients with HR+, HER2-advanced breast cancer: MONARCH 2 & 3 trials
    Toi, Masakazu
    Inoue, Kenichi
    Masuda, Norikazu
    Iwata, Hiroji
    Sohn, Joohyuk
    Hae Park, In
    Im, Seock-Ah
    Chen, Shin-Cheh
    Enatsu, Sotaro
    Turner, P. Kellie
    Andre, Valerie A. M.
    Hardebeck, Molly C.
    Sakaguchi, Sachi
    Goetz, Matthew P.
    Sledge, George W., Jr.
    CANCER SCIENCE, 2021, 112 (06) : 2381 - 2392
  • [4] MONARCH 2: Overall survival of abemaciclib plus fulvestrant in patients with HR+, HER2-advanced breast cancer
    Sledge, G. W.
    Toi, M.
    Neven, P.
    Sohn, J.
    Inoue, K.
    Pivot, X.
    Burdaeva, O.
    Okera, M.
    Masuda, N.
    Kaufman, P. A.
    Koh, H.
    Grischke, E-M.
    Conte, P. F.
    Lu, Y.
    Barriga, S.
    Hurt, K.
    Frenzel, M.
    Johnston, S. R. D.
    Llombart-Cussac, A.
    ANNALS OF ONCOLOGY, 2019, 30 : 856 - 856
  • [5] MONARCH 2: Abemaciclib in combination with fulvestrant in patients with HR+/HER2-advanced breast cancer who progressed on endocrine therapy
    Sledge, George W.
    Toi, Masakazu
    Neven, Patrick
    Sohn, Joohyuk
    Inoue, Kenichi
    Pivot, Xavier B.
    Burdaeva, Olga Nikolaevna
    Okera, Meena
    Masuda, Norikazu
    Kaufman, Peter A.
    Koh, Han A.
    Grischke, Eva-Maria
    Frenzel, Martin
    Lin, Yong
    Barriga, Susana
    Smith, Ian C.
    Bourayou, Nawel
    Llombart-Cussac, Antonio
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [6] MONARCH 3: Final overall survival results of abemaciclib plus a nonsteroidal aromatase inhibitor as first-line therapy for HR+, HER2-advanced breast cancer
    Goetz, Matthew
    Toi, Masakazu
    Huober, Jens
    Sohn, Joo Hyuk
    Tredan, Olivier
    Park, Inhae
    Campone, Mario
    Chen, Shin-Cheh
    Manso, Luis Manual
    Paluch-Shimon, Shani
    Freedman, Orit C.
    Andre, Valerie
    Saha, Abhijoy
    van Hal, Gertjan
    Shahir, Ashwin
    Iwata, Hiroji
    Johnston, Stephen R. D.
    O'Shaughnessy, Joyce
    Pivot, Xavier
    Tolaney, Sara
    Hurvitz, Sara
    Llombart, Antonio
    CANCER RESEARCH, 2024, 84 (09)
  • [7] Monarch 2: Interim Overall Survival of Abemaciclib Plus Fulvestrant in Patients with HR+, HER2-Advanced Breast Cancer
    Grischke, Eva Maria
    Sledge, George W.
    Toi, Masakazu
    Neven, Patrick
    Sohn, Joo Hyuk
    Inoue, Kenichi
    Pivot, Xavier
    Burdaeva, Olga
    Masuda, Norikazu
    Kaufman, Peter
    Koh, Han
    Conte, Pierfranco
    Barriga, Susana
    Hurt, Karla
    Frenzel, Martin
    Johnston, Stephen
    Llombart-Cussac, Antonio
    ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 : 15 - 15
  • [8] Management of abemaciclib-associated adverse events in patients with HR+/HER2-advanced breast cancer: analysis of the MONARCH trials
    Rugo, H. S.
    Huober, J.
    Llombart-Cussac, A.
    Toi, M.
    Tolaney, S.
    Andre, V.
    Barriga, S.
    Forrester, T.
    Sledge, Jr G. W.
    Goetz, M. P.
    ONCOLOGY RESEARCH AND TREATMENT, 2019, 42 : 289 - 289
  • [9] MONARCH 3 final PFS: a randomized study of abemaciclib as initial therapy for advanced breast cancer
    Johnston, Stephen
    Martin, Miguel
    Di Leo, Angelo
    Im, Seock-Ah
    Awada, Ahmad
    Forrester, Tammy
    Frenzel, Martin
    Hardebeck, Molly C.
    Cox, Joanne
    Barriga, Susana
    Toi, Masakazu
    Iwata, Hiroji
    Goetz, Matthew P.
    NPJ BREAST CANCER, 2019, 5 (1)
  • [10] MONARCH 3 final PFS: a randomized study of abemaciclib as initial therapy for advanced breast cancer
    Stephen Johnston
    Miguel Martin
    Angelo Di Leo
    Seock-Ah Im
    Ahmad Awada
    Tammy Forrester
    Martin Frenzel
    Molly C. Hardebeck
    Joanne Cox
    Susana Barriga
    Masakazu Toi
    Hiroji Iwata
    Matthew P. Goetz
    npj Breast Cancer, 5
12345